<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001036</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 236</org_study_id>
    <nct_id>NCT00001036</nct_id>
  </id_info>
  <brief_title>The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection</brief_title>
  <official_title>Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine and Thymosin Alpha 1 in HIV-Positive, Asymptomatic and Symptomatic Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To determine the safety of thymosin alpha 1 given twice weekly in a regimen of daily oral&#xD;
      zidovudine (AZT) and biweekly polyethylene glycolated interleukin-2 (PEG IL-2). To determine&#xD;
      the effect of thymosin alpha 1 and PEG IL-2 in combination with AZT on immunologic and&#xD;
      pharmacokinetic markers.&#xD;
&#xD;
      AIDS is characterized by diminished T helper cell number and function. Thymosin alpha 1&#xD;
      appears to both increase IL-2 receptors on lymphocytes in vitro and enhance lymphocyte&#xD;
      maturation in vivo; thus, the drug may further enhance the CD4 T cell levels in patients&#xD;
      receiving AZT and PEG IL-2.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AIDS is characterized by diminished T helper cell number and function. Thymosin alpha 1&#xD;
      appears to both increase IL-2 receptors on lymphocytes in vitro and enhance lymphocyte&#xD;
      maturation in vivo; thus, the drug may further enhance the CD4 T cell levels in patients&#xD;
      receiving AZT and PEG IL-2.&#xD;
&#xD;
      Patients are stabilized on oral AZT daily for 8 weeks and then begin receiving bolus&#xD;
      infusions of PEG IL-2 every other week for at least four doses. Thymosin alpha 1 (given SC)&#xD;
      is then added to this regimen twice weekly for 4 weeks. If no significant toxicity occurs,&#xD;
      thymosin alpha 1 is increased to and administered along with scheduled doses of PEG IL-2 for&#xD;
      an additional 8 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>12</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymalfasin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interleukin-2, Polyethylene Glycolated</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Prophylactic pentamidine for Pneumocystis carinii.&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV seropositivity.&#xD;
&#xD;
          -  CD4 count &gt; 50 and &lt; 200 cells/mm3.&#xD;
&#xD;
          -  No active opportunistic infections.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Concurrent neoplasms other than basal cell carcinoma of the skin, in situ carcinoma of&#xD;
             the cervix, or Kaposi's sarcoma.&#xD;
&#xD;
          -  Significant cardiac disease or CNS lesions or other neurologic abnormalities.&#xD;
&#xD;
          -  Score of &gt; 0.5 on ACTG AIDS Dementia Complex staging.&#xD;
&#xD;
          -  Major organ allograft.&#xD;
&#xD;
          -  Intolerance to AZT at 500 mg/day.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Antihypertensive medication other than diuretics.&#xD;
&#xD;
          -  Chemotherapy, hormonal therapy, or other immunotherapy.&#xD;
&#xD;
          -  Other investigational drugs, agents, or devices.&#xD;
&#xD;
          -  Beta-blockers.&#xD;
&#xD;
          -  Non-topical steroids.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Radiation therapy.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Known anti-HIV medication (other than AZT) or known immunomodulators (e.g., systemic&#xD;
             steroids, interferons, interleukins) or other chemotherapy within 30 days prior to&#xD;
             study entry.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Transfusion within 4 weeks prior to study entry.&#xD;
&#xD;
          -  Radiation within 30 days prior to study entry.&#xD;
&#xD;
        Active substance abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>TC Merigan</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Univ Med Ctr</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>943055107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ramachandran R, Katzenstein DA, Winters MA, Kundu SK, Merigan TC. Polyethylene glycol-modified interleukin-2 and thymosin alpha 1 in human immunodeficiency virus type 1 infection. J Infect Dis. 1996 Apr;173(4):1005-8. doi: 10.1093/infdis/173.4.1005.</citation>
    <PMID>8603940</PMID>
  </reference>
  <verification_date>October 1996</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>July 29, 2008</last_update_submitted>
  <last_update_submitted_qc>July 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2008</last_update_posted>
  <keyword>T-Lymphocytes</keyword>
  <keyword>Polyethylene Glycols</keyword>
  <keyword>Interleukin-2</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Adjuvants, Immunologic</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Zidovudine</keyword>
  <keyword>thymosin alpha(1)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Thymalfasin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

